Adial Pharmaceuticals Statistics
Share Statistics
Adial Pharmaceuticals has 6.57M
shares outstanding. The number of shares has increased by 55.31%
in one year.
| Shares Outstanding | 6.57M |
| Shares Change (YoY) | 55.31% |
| Shares Change (QoQ) | 1.54% |
| Owned by Institutions (%) | 0.06% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 704 |
| FTD / Avg. Volume | 0.08% |
Short Selling Information
The latest short interest is 217.06K, so 3.3% of the outstanding
shares have been sold short.
| Short Interest | 217.06K |
| Short % of Shares Out | 3.3% |
| Short % of Float | 3.35% |
| Short Ratio (days to cover) | 3.98 |
Valuation Ratios
The PE ratio is -1.42 and the forward
PE ratio is -0.6.
Adial Pharmaceuticals's PEG ratio is
0.02.
| PE Ratio | -1.42 |
| Forward PE | -0.6 |
| PS Ratio | 0 |
| Forward PS | 0.1 |
| PB Ratio | 4.62 |
| P/FCF Ratio | -2.71 |
| PEG Ratio | 0.02 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Adial Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.16,
with a Debt / Equity ratio of 0.
| Current Ratio | 4.16 |
| Quick Ratio | 4.16 |
| Debt / Equity | 0 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-2,639,490.2 |
| Employee Count | 5 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -61.76% in the
last 52 weeks. The beta is 1.26, so Adial Pharmaceuticals's
price volatility has been higher than the market average.
| Beta | 1.26 |
| 52-Week Price Change | -61.76% |
| 50-Day Moving Average | 0.72 |
| 200-Day Moving Average | 0.93 |
| Relative Strength Index (RSI) | 45.87 |
| Average Volume (20 Days) | 877,116 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -8.28M |
| Net Income | -13.2M |
| EBITDA | -13.2M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -0.71 |
Full Income StatementBalance Sheet
The company has 3.75M in cash and 0 in
debt, giving a net cash position of 3.75M.
| Cash & Cash Equivalents | 3.75M |
| Total Debt | n/a |
| Net Cash | n/a |
| Retained Earnings | -82M |
| Total Assets | 5.04M |
| Working Capital | 3.08M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -6.92M
and capital expenditures 0, giving a free cash flow of -6.92M.
| Operating Cash Flow | -6.92M |
| Capital Expenditures | n/a |
| Free Cash Flow | -6.92M |
| FCF Per Share | -0.37 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
